Ann: BNO - FDA Fast Track Application, page-8

The application outlines the non-clinical and clinical data for BNC210 showing efficacy in animal models representing symptoms of PTSD, such as anxiety, hyperarousal and fear extinction, and an improved clinical and non-clinical safety and tolerability profile compared to the standard of care therapies for PTSD which are the SSRIs, sertraline and paroxetine.
The SP can only go up ,at this stage it is only 10% of pre crash value.
The market for PTSD medication is worth billions and we already know that it works in animal models.